On his recent blog posts, Clay Siegall focussed on a variety of issues across the society. From social policies to climate change and ecosystem. With most of the articles linked to National Public Radio (NPR), all that appears on Clay’s blog posts are nerve striking both emotionally and intellectually.
Most notably is the contemporary issue of the direction taken by the USA President to pull out the climate change pact earlier signed by his predecessor. Another article on the same issue shows how climate change affects coffee farmers in a country in Africa, Uganda. On the other end, a highly emotional article about terminal patients who are given a choice to end their lives by the aid of a doctor shows how this aid to die requires more than just a law. Then there is an article about Alan Alda; an actor, New York Times best-selling author and longtime host at PBS. He has spent hours trying to harmonize the gap within different sectors of science and academics. In his new book, he tries to simply how people understand science.
About Clay Siegall
Clay currently doubles up as the President and CEO of Seattle Genetics. He is also the Chairman of the Board. A company he founded in 1988 which deals in oncology biotechnology for cancer treatment. The company has earned a worldwide reputation as the best in the production of antibody drug conjugate (ADC) technology.
Recently, as the CEO of the company Clay has sold 10,423 shares of the company’s stock on Monday, June 5th. On average it was sold at $65.21, for a transaction of $679,683.83. This was made public in a filing with the Securities & Exchange Commission.
Since its commencement in 1988, Clay has managed to steadily lead the company to higher standards. Seattle Genetics has so far acquired multiple licenses for antibody drug conjugate technology including with Astellas, Genentech (Roche), AbbVie, GlaxosSmithKline, and Pfizer. These deals have been able to generate more than 350 million dollars to date.
Also, through his efforts, the company has seen capital rise to more than 1.2 billion dollars through public and private financings including its initial public offering (IPO) in 2001.